Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Paradoxical Suppression of Atherosclerosis in the Absence of microRNA-146a.

Cheng HS, Besla R, Li A, Chen Z, Shikatani EA, Nazari-Jahantigh M, Hammoutène A, Nguyen MA, Geoffrion M, Cai L, Khyzha N, Li T, MacParland SA, Husain M, Cybulsky MI, Boulanger CM, Temel RE, Schober A, Rayner KJ, Robbins CS, Fish JE.

Circ Res. 2017 Aug 4;121(4):354-367. doi: 10.1161/CIRCRESAHA.116.310529. Epub 2017 Jun 21.

2.

Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis.

Mihara M, Ohsugi Y, Kishimoto T.

Open Access Rheumatol. 2011 Feb 25;3:19-29. eCollection 2011. Review.

3.

Sleeping Beauty Transposon Vectors in Liver-directed Gene Delivery of LDLR and VLDLR for Gene Therapy of Familial Hypercholesterolemia.

Turunen TA, Kurkipuro J, Heikura T, Vuorio T, Hytönen E, Izsvák Z, Ylä-Herttuala S.

Mol Ther. 2016 Mar;24(3):620-35. doi: 10.1038/mt.2015.221. Epub 2015 Dec 16.

4.

Disease-modifying antirheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis: a retrospective cohort study.

Desai RJ, Eddings W, Liao KP, Solomon DH, Kim SC.

Arthritis Care Res (Hoboken). 2015 Apr;67(4):457-66. doi: 10.1002/acr.22483.

5.

Interleukin 6 and rheumatoid arthritis.

Yoshida Y, Tanaka T.

Biomed Res Int. 2014;2014:698313. doi: 10.1155/2014/698313. Epub 2014 Jan 12. Review.

6.

Marked independent relationship between circulating interleukin-6 concentrations and endothelial activation in rheumatoid arthritis.

Dessein PH, Solomon A, Woodiwiss AJ, Norton GR, Tsang L, Gonzalez-Gay MA.

Mediators Inflamm. 2013;2013:510243. doi: 10.1155/2013/510243. Epub 2013 Dec 21.

7.

Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study.

McInnes IB, Thompson L, Giles JT, Bathon JM, Salmon JE, Beaulieu AD, Codding CE, Carlson TH, Delles C, Lee JS, Sattar N.

Ann Rheum Dis. 2015 Apr;74(4):694-702. doi: 10.1136/annrheumdis-2013-204345. Epub 2013 Dec 24.

8.

Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis.

Ogata A, Hirano T, Hishitani Y, Tanaka T.

Clin Med Insights Arthritis Musculoskelet Disord. 2012;5:27-42. doi: 10.4137/CMAMD.S7371. Epub 2012 Mar 5.

9.
10.

Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthritis model: a translational study.

Balagué C, Pont M, Prats N, Godessart N.

Br J Pharmacol. 2012 Jun;166(4):1320-32. doi: 10.1111/j.1476-5381.2012.01836.x.

11.

The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis.

Hashizume M, Mihara M.

Arthritis. 2011;2011:765624. doi: 10.1155/2011/765624. Epub 2011 May 26.

12.

Requirement of JIP1-mediated c-Jun N-terminal kinase activation for obesity-induced insulin resistance.

Morel C, Standen CL, Jung DY, Gray S, Ong H, Flavell RA, Kim JK, Davis RJ.

Mol Cell Biol. 2010 Oct;30(19):4616-25. doi: 10.1128/MCB.00585-10. Epub 2010 Aug 2.

Supplemental Content

Support Center